|
1
|
Girardi D, Barrichello A, Fernandes G and
Pereira A: Targeting the hedgehog pathway in cancer: Current
evidence and future perspectives. Cells. 8:1532019.
|
|
2
|
Niyaz M, Khan MS and Mudassar S: Hedgehog
signaling: An achilles' heel in cancer. Transl Oncol. 12:1334–1344.
2019.
|
|
3
|
Pak E and Segal RA: Hedgehog signal
transduction: Key players, oncogenic drivers, and cancer therapy.
Dev Cell. 38:333–344. 2016.
|
|
4
|
Sari IN, Phi LTH, Jun N, Wijaya YT, Lee S
and Kwon HY: Hedgehog signaling in cancer: A prospective
therapeutic target for eradicating cancer stem cells. Cells.
7:2082018.
|
|
5
|
Peer E, Tesanovic S and Aberger F:
Next-generation hedgehog/GLI pathway inhibitors for cancer therapy.
Cancers (Basel). 11:5382019.
|
|
6
|
Katoh Y and Katoh M: Hedgehog target
genes: Mechanisms of carcinogenesis induced by aberrant hedgehog
signaling activation. Curr Mol Med. 9:873–886. 2009.
|
|
7
|
Barnes EA, Heidtman KJ and Donoghue DJ:
Constitutive activation of the shh-ptc1 pathway by a patched1
mutation identified in BCC. Oncogene. 24:902–915. 2005.
|
|
8
|
Tao Y, Mao J, Zhang Q and Li L:
Overexpression of hedgehog signaling molecules and its involvement
in triple-negative breast cancer. Oncol Lett. 2:995–1001. 2011.
|
|
9
|
van den Brink GR, Bleuming SA, Hardwick
JC, Schepman BL, Offerhaus GJ, Keller JJ, Nielsen C, Gaffield W,
van Deventer SJ, Roberts DJ and Peppelenbosch MP: Indian hedgehog
is an antagonist of Wnt signaling in colonic epithelial cell
differentiation. Nat Genet. 36:277–282. 2004.
|
|
10
|
Yoshikawa K, Shimada M, Miyamoto H,
Higashijima J, Miyatani T, Nishioka M, Kurita N, Iwata T and Uehara
H: Sonic hedgehog relates to colorectal carcinogenesis. J
Gastroenterol. 44:1113–1117. 2009.
|
|
11
|
Rajurkar M, De Jesus-Monge WE, Driscoll
DR, Appleman VA, Huang H, Cotton JL, Klimstra DS, Zhu LJ, Simin K,
Xu L, et al: The activity of Gli transcription factors is essential
for Kras-induced pancreatic tumorigenesis. Proc Natl Acad Sci USA.
109:E1038–E1047. 2012.
|
|
12
|
Wang Y, Ding Q, Yen CJ, Xia W, Izzo JG,
Lang JY, Li CW, Hsu JL, Miller SA, Wang X, et al: The crosstalk of
mTOR/S6K1 and hedgehog pathways. Cancer Cell. 21:374–387. 2012.
|
|
13
|
Pandolfi S, Montagnani V, Penachioni JY,
Vinci MC, Olivito B, Borgognoni L and Stecca B: WIP1 phosphatase
modulates the Hedgehog signaling by enhancing GLI1 function.
Oncogene. 32:4737–4747. 2013.
|
|
14
|
Lauth M, Bergström A, Shimokawa T and
Toftgard R: Inhibition of GLI-mediated transcription and tumor cell
growth by small-molecule antagonists. Proc Natl Acad Sci USA.
104:8455–8460. 2007.
|
|
15
|
Agyeman A, Jha BK, Mazumdar T and Houghton
JA: Mode and specificity of binding of the small molecule GANT61 to
GLI determines inhibition of GLI-DNA binding. Oncotarget.
5:4492–4503. 2014.
|
|
16
|
Hyman JM, Firestone AJ, Heine VM, Zhao Y,
Ocasio CA, Han K, Sun M, Rack PG, Sinha S, Wu JJ, et al:
Small-molecule inhibitors reveal multiple strategies for Hedgehog
pathway blockade. Proc Natl Acad Sci USA. 106:14132–14137.
2009.
|
|
17
|
Livak KJ and Schmittgen TD: Analysis of
relative gene expression data using real-time quantitative PCR and
the 2(-Delta Delta C(T)) Method. Methods. 25:402–408. 2001.
|
|
18
|
Chou TC: Theoretical basis, experimental
design, and computerized simulation of synergism and antagonism in
drug combination studies. Pharmacol Rev. 58:621–681. 2006.
|
|
19
|
Chou TC and Talalay P: Quantitative
analysis of dose-effect relationships: The combined effects of
multiple drugs or enzyme inhibitors. Adv Enzyme Regul. 22:27–55.
1984.
|
|
20
|
Garcia-Santisteban I, Llopis A, Krenning
L, Vallejo-Rodríguez J, van den Broek B, Zubiaga AM and Medema RH:
Sustained CHK2 activity, but not ATM activity, is critical to
maintain a G1 arrest after DNA damage in untransformed cells. BMC
Biol. 19:352021.
|
|
21
|
De Vita F, Riccardi M, Malanga D, Scrima
M, De Marco C and Viglietto G: PKC-dependent phosphorylation of p27
at T198 contributes to p27 stabilization and cell cycle arrest.
Cell Cycle. 11:1583–1592. 2012.
|
|
22
|
Sakaguchi K, Herrera JE, Saito S, Miki T,
Bustin M, Vassilev A, Anderson CW and Appella E: DNA damage
activates p53 through a phosphorylation-acetylation cascade. Genes
Dev. 12:2831–2841. 1998.
|
|
23
|
Mazzà D, Infante P, Colicchia V, Greco A,
Alfonsi R, Siler M, Antonucci L, Po A, De Smaele E, Ferretti E, et
al: PCAF ubiquitin ligase activity inhibits Hedgehog/Gli1 signaling
in p53-dependent response to genotoxic stress. Cell Death Differ.
20:1688–1697. 2013.
|
|
24
|
Murphy T and Yee KWL: Cytarabine and
daunorubicin for the treatment of acute myeloid leukemia. Expert
Opin Pharmacother. 18:1765–1780. 2017.
|
|
25
|
Li T, Liao X, Lochhead P, Morikawa T,
Yamauchi M, Nishihara R, Inamura K, Kim SA, Mima K, Sukawa Y, et
al: SMO expression in colorectal cancer: Associations with
clinical, pathological, and molecular features. Ann Surg Oncol.
21:4164–4173. 2014.
|
|
26
|
Maréchal R, Bachet JB, Calomme A, Demetter
P, Delpero JR, Svrcek M, Cros J, Bardier-Dupas A, Puleo F, Monges
G, et al: Sonic hedgehog and Gli1 expression predict outcome in
resected pancreatic adenocarcinoma. Clin Cancer Res. 21:1215–1224.
2015.
|
|
27
|
Rahman MM, Hazan A, Selway JL, Herath DS,
Harwood CA, Pirzado MS, Atkar R, Kelsell DP, Linton KJ, Philpott MP
and Neill GW: A novel mechanism for activation of GLI1 by nuclear
SMO that escapes anti-SMO inhibitors. Cancer Res. 78:2577–2588.
2018.
|
|
28
|
Niyaz M, Khan MS, Wani RA, Shah OJ, Besina
S and Mudassar S: Nuclear localization and overexpression of
smoothened in pancreatic and colorectal cancers. J Cell Biochem.
120:11941–11948. 2019.
|
|
29
|
Harvey J, Bonnem E, Grady K, Goodman A and
Schein P: Phase II study of daunorubicin in previously untreated
patients with advanced colorectal carcinoma. Med Pediatr Oncol.
13:30–31. 1985.
|
